BioSpace

FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months

If approved, Ascendis’ TransCon CNP would become the second therapy for achondroplasia, challenging BioMarin’s Voxzogo.
Fierce Biotech

FDA delays decision on Ascendis' dwarfism prospect by 3 months

The FDA has delayed a decision on Ascendis Pharma’s dwarfism drug candidate TransCon CNP, pushing back the deadline by three ...
Yahoo

BioMarin's dwarfism therapy gets FDA nod for expanded use

(Reuters) -The U.S. health regulator on Friday approved the expanded use of BioMarin Pharmaceutical's once-daily injection to treat children under the age of 5 with the most common form of ...

US FDA extends review of Ascendis Pharma's therapy for children with dwarfism

The U.S. Food and Drug Administration on Tuesday extended its review of Ascendis Pharma's therapy for children with a rare ...
MM&M

BridgeBio sells partial rights to dwarfism drug for $100M

BridgeBio licensed the exclusive Japanese rights to develop and sell an experimental dwarfism drug to Tokyo-based pharma firm Kyowa Kirin, firms said earlier this week. Terms of the deal call for ...
Seeking Alpha

BridgeBio grants Japanese rights to Kyowa Kirin for dwarfism drug

BridgeBio (NASDAQ:BBIO) has granted an exclusive license to Kyowa Kirin for the Japanese development and commercialization rights to its dwarfism drug infigratinib. Under the deal, Kyowa Kirin will ...
Northcountrypublicradio.org

Controversial Dwarfism Drug Helps Regulate Bone Development In Children

BioMarin Pharmaceutical researchers have created a controversial drug that helps regulate bone development in children with the most common type... Controversial Dwarfism Drug Helps Regulate Bone ...